Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zollo

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Natural Products|April 11, 2000
New pyridinium alkaloids from a marine sponge of the genus Spongia with a human phospholipase A(2) inhibitor profileS De Marino, M Iorizzi, F Zollo, et al.
Chemosphere|October 26, 2010
Bisphenol A content in fish caught in two different sites of the Tyrrhenian Sea (Italy)L Mita, M Bianco, E Viggiano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2024
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)C Proto, M Ganzinelli, S Manglaviti, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Natural Products|April 11, 2000
New pyridinium alkaloids from a marine sponge of the genus Spongia with a human phospholipase A(2) inhibitor profileS De Marino, M Iorizzi, F Zollo, et al.
Chemosphere|October 26, 2010
Bisphenol A content in fish caught in two different sites of the Tyrrhenian Sea (Italy)L Mita, M Bianco, E Viggiano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2024
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)C Proto, M Ganzinelli, S Manglaviti, et al.
Pageof 2